{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/prescribing-information/topical-prostaglandin-analogues-prostamides/","result":{"pageContext":{"chapter":{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides","depth":2,"htmlHeader":"<!-- begin field ba7440a8-2b94-4d7c-bcfd-08fc87ea31a5 --><h2>Topical prostaglandin analogues and prostamides</h2><!-- end field ba7440a8-2b94-4d7c-bcfd-08fc87ea31a5 -->","summary":"","htmlStringContent":"<!-- begin item 9bac53af-7a6a-40d6-98d7-51ec3bec5717 --><!-- end item 9bac53af-7a6a-40d6-98d7-51ec3bec5717 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b2bd9e39-05d3-5cb5-a530-7b79841d5ade","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field 58dc8c8d-9d10-4313-8657-b5fce34417f8 --><h3>Which topical prostaglandin analogues and prostamides are available for the treatment of glaucoma?</h3><!-- end field 58dc8c8d-9d10-4313-8657-b5fce34417f8 -->","summary":"","htmlStringContent":"<!-- begin item 70aebcbe-9297-4701-99f1-8171a80d3b7b --><!-- begin field 6f2cf2b4-a508-4f55-8472-2a0b0cf98d7e --><ul><li><strong>Topical prostaglandin analogues available for the treatment of glaucoma include:</strong><ul><li>Latanoprost. </li><li>Travoprost. </li><li>Tafluprost. </li></ul></li><li><strong>Bimatoprost is classed as a prostamide as it has a slightly different chemical structure to prostaglandin analogues, but is often included in the same group.</strong></li><li>The dose for each preparation is usually one drop once daily, preferably in the evening.</li><li>Preservative-free preparations (without benzalkonium chloride) of latanoprost, travoprost, tafluprost, and bimatoprost eye drops are available. These are more expensive than the standard eye drops but may be prescribed by an ophthalmologist to a person with an allergy to benzalkonium chloride.</li><li>Combination preparations containing timolol are also available.</li><li>Topical prostaglandin analogues and prostamides are not licensed for children under 18 years of age.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 6f2cf2b4-a508-4f55-8472-2a0b0cf98d7e --><!-- end item 70aebcbe-9297-4701-99f1-8171a80d3b7b -->","subChapters":[]},{"id":"3caf959f-3e14-5d22-9288-f38920cf7412","slug":"action","fullItemName":"Action","depth":3,"htmlHeader":"<!-- begin field d13c375d-46e4-4776-b1d5-4727f822c8fd --><h3>How do topical prostaglandin analogues work?</h3><!-- end field d13c375d-46e4-4776-b1d5-4727f822c8fd -->","summary":"","htmlStringContent":"<!-- begin item c8a218f5-e385-4e90-96d0-72adb1c89ab5 --><!-- begin field 2a40f213-f891-43a4-b1fe-f64a9d0b1b7c --><ul><li>Topical prostaglandin analogues and prostamides reduce intraocular pressure by enhancing uveoscleral outflow of aqueous humour. They may also have some effect to increase the trabecular meshwork outflow of aqueous humour.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 2a40f213-f891-43a4-b1fe-f64a9d0b1b7c --><!-- end item c8a218f5-e385-4e90-96d0-72adb1c89ab5 -->","subChapters":[]},{"id":"0a568d81-0ffa-57b3-ab23-3771523fddb9","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 5b41f10b-f362-4147-bbca-cb92beec6e22 --><h3>What are the cautions and contraindications when prescribing topical prostaglandin analogues and prostamides?</h3><!-- end field 5b41f10b-f362-4147-bbca-cb92beec6e22 -->","summary":"","htmlStringContent":"<!-- begin item a6c983f8-0694-4a34-9375-0c67207855e2 --><!-- begin field a79ae2ae-1e28-49f0-a916-80459f99e4df --><ul><li><strong>Use</strong><strong> prostaglandin analogues and prostamides</strong> <strong>with caution</strong> in people with aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses, and in people with known risk factors for cystoid macular oedema, iritis, uveitis, or a history of significant ocular viral infections. Also, use with care in people with chronic obstructive pulmonary disease (COPD), asthma, or compromised respiratory function.</li><li><strong>For pregnant women,</strong> the manufacturers advise:<ul><li>Avoiding bimatoprost, tafluprost, and travoprost unless potential benefit outweighs risk.</li><li>Avoiding latanoprost.</li></ul></li><li><strong>For breastfeeding women,</strong> the manufacturers advise avoiding all prostaglandin analogues and prostamides.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field a79ae2ae-1e28-49f0-a916-80459f99e4df --><!-- end item a6c983f8-0694-4a34-9375-0c67207855e2 -->","subChapters":[]},{"id":"f071f86e-0f4a-5717-b0d1-7e10309c7132","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 40d96ce8-4c18-4a17-99af-7505f8113920 --><h3>What key adverse effects are associated with topical prostaglandin analogues?</h3><!-- end field 40d96ce8-4c18-4a17-99af-7505f8113920 -->","summary":"","htmlStringContent":"<!-- begin item 90aee35a-84cc-43f7-b4f3-6f28d945d726 --><!-- begin field 9654f0a8-6840-42e8-b7c6-047b84689f59 --><ul><li><strong>Local adverse effects include:</strong><ul><li>Increased brown pigmentation in the iris of the treated eye. This is especially noticeable when the iris is mixed-coloured (blue-brown, grey-brown, yellow-brown, or green-brown).</li><li>Increased pigmentation of peri-ocular skin.</li><li>Darkening, thickening, and lengthening of the eyelashes.</li><li>Blepharitis.</li><li>Macular oedema has been reported as potential adverse effect of tafluprost.</li><li>Ocular pain and irritation.</li><li>Conjunctival hyperaemia.</li><li>Dry eyes.</li><li>Eyelid oedema and rash, keratitis, blurred vision, and conjunctivitis have also been rarely reported.</li><li>Allergic reaction to the active drug or preservative.</li><li>Periorbital and lid changes resulting in deepening of the eyelid sulcus (very rare).</li></ul></li><li><strong>Systemic adverse</strong><strong> </strong><strong>effects are uncommon</strong>. Those reported include:<ul><li>Dyspnoea.</li><li>Exacerbation of asthma.</li><li>Dizziness.</li><li>Arthralgia</li><li>Myalgia.</li><li>Iritis.</li><li>Uveitis.</li><li>Headache.</li><li>Photophobia.</li><li>Hallucinations.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020c</a>]</p><!-- end field 9654f0a8-6840-42e8-b7c6-047b84689f59 --><!-- end item 90aee35a-84cc-43f7-b4f3-6f28d945d726 -->","subChapters":[]},{"id":"c08d3b08-3558-5b41-a7f6-6b1d884a08af","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field c64c0d53-5efb-405c-905f-0d8095d477b1 --><h3>What drug interactions are important with topical prostaglandin analogues?</h3><!-- end field c64c0d53-5efb-405c-905f-0d8095d477b1 -->","summary":"","htmlStringContent":"<!-- begin item 17a128c1-0ad3-4267-a8cc-47ebe46c261a --><!-- begin field 204066f5-70cd-4ff0-a3b8-2efd3c112ce1 --><ul><li>There are no important common drug interactions with topical prostaglandin analogues. However, the concurrent use of two or more topical prostaglandin analogues or derivatives is not recommended as there are reports of elevations in intraocular pressure after such use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Preston, 2020</a>]</p><!-- end field 204066f5-70cd-4ff0-a3b8-2efd3c112ce1 --><!-- end item 17a128c1-0ad3-4267-a8cc-47ebe46c261a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}